Monte Rosa Therapeutics Inc (GLUE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $800.67M
Last updated: Nov 17, 2026 at 4:10 PM ET
Monte Rosa Therapeutics Inc (GLUE) Stock Chart
Monte Rosa Therapeutics (GLUE) has a latest price of $9.07 on Nov 17, 2026, 64.8% below its 52-week high of $25.77. Its price fell 36.8% over the past 12 months. The month-end price fell 54.1% over the 5 years through Oct 2026, a compound annual decline of 14.4%.
Price Chart
From Jun 2021 to Oct 2026, its highest month-end close was $35.69 in Aug 2021 and its lowest $3.10 in Nov 2023, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart GLUE with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for GLUE.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 42.5%, and over 6 months it fell 48.4%. The month-end price rose 216.5% over the 3 years through Oct 2026, a compound annual rate of 46.8%.
| Period | Change |
|---|---|
| 1 month | -14.9% |
| 3 months | -42.5% |
| 6 months | -48.4% |
| 12 months | -36.8% |
| 12 months, with dividends | -36.8% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +216.5% | +46.8% |
| 5 years | -54.1% | -14.4% |
Price by Year
Its best calendar year was 2025, when the price rose 125.9%, and its weakest was 2022, when it fell 62.7%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $10.76 | -31.4% |
| 2025 | $15.68 | +125.9% |
| 2024 | $6.94 | +22.8% |
| 2023 | $5.65 | -25.8% |
| 2022 | $7.61 | -62.7% |
Trading Range
The price is 18.3% below its 50-day average of $11.10 and 45.5% below its 200-day average of $16.63.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $9.07 | |
| 52-week high | $25.77 | -64.8% |
| 52-week low | $8.95 | +1.3% |
| 50-day average | $11.10 | -18.3% |
| 200-day average | $16.63 | -45.5% |
Price Risk
Over 3 years, its largest fall from a peak was 64.3%.
| Measure | Value |
|---|---|
| 1-year beta | 0.93 |
| Largest fall, 1 year | -64.2% |
| Largest fall, 3 years | -64.3% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About GLUE
What is GLUE's 1-year price change?
Monte Rosa Therapeutics's price fell 36.8% over the past 12 months. With dividends included, the 12-month total return was -36.8%.
What is GLUE's 5-year price change?
Monte Rosa Therapeutics's month-end price fell 54.1% over the 5 years through Oct 2026, a compound annual decline of 14.4%. These figures leave out dividends.
What is GLUE's 52-week high and low?
Monte Rosa Therapeutics's 52-week high is $25.77 and its 52-week low is $8.95. Its latest price of $9.07 on Nov 17, 2026 is 64.8% below the high.
What is GLUE's beta?
Monte Rosa Therapeutics's 1-year beta against the S&P 500 is 0.93, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 64.2%.
Is the GLUE chart free?
Yes. Advanced Charting for GLUE is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
GLUE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors